William Brand Feldman, D.Phil., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Patents as Topic | 7 | 2024 | 111 | 5.100 |
Why?
|
Drug Costs | 17 | 2024 | 1183 | 4.040 |
Why?
|
Nebulizers and Vaporizers | 10 | 2023 | 139 | 3.570 |
Why?
|
Medicare Part D | 9 | 2024 | 355 | 3.220 |
Why?
|
Drug Industry | 9 | 2024 | 788 | 2.230 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 7 | 2024 | 3204 | 2.110 |
Why?
|
Prescription Drugs | 9 | 2024 | 631 | 2.100 |
Why?
|
Economic Competition | 5 | 2023 | 219 | 1.880 |
Why?
|
United States Food and Drug Administration | 12 | 2024 | 1664 | 1.830 |
Why?
|
Bronchodilator Agents | 5 | 2024 | 512 | 1.810 |
Why?
|
Negotiating | 5 | 2024 | 150 | 1.780 |
Why?
|
Drug Approval | 7 | 2024 | 814 | 1.560 |
Why?
|
Asthma | 7 | 2023 | 6211 | 1.550 |
Why?
|
Drugs, Generic | 7 | 2024 | 448 | 1.500 |
Why?
|
Nonprescription Drugs | 2 | 2022 | 118 | 1.490 |
Why?
|
Trust | 2 | 2024 | 530 | 1.270 |
Why?
|
Informed Consent | 4 | 2022 | 1008 | 1.260 |
Why?
|
Hypoglycemic Agents | 4 | 2024 | 3081 | 1.040 |
Why?
|
Pharmaceutical Preparations | 6 | 2024 | 1088 | 1.010 |
Why?
|
Phenylpropionates | 1 | 2024 | 35 | 0.930 |
Why?
|
Prescription Fees | 2 | 2024 | 153 | 0.930 |
Why?
|
Epidermolysis Bullosa | 1 | 2024 | 29 | 0.920 |
Why?
|
Epidermolysis Bullosa Dystrophica | 1 | 2024 | 29 | 0.910 |
Why?
|
European Union | 1 | 2024 | 157 | 0.890 |
Why?
|
United States | 43 | 2024 | 72339 | 0.860 |
Why?
|
Administration, Inhalation | 5 | 2024 | 1156 | 0.850 |
Why?
|
Liver Function Tests | 1 | 2024 | 523 | 0.830 |
Why?
|
Pyridazines | 1 | 2024 | 202 | 0.820 |
Why?
|
Cost Control | 1 | 2024 | 628 | 0.790 |
Why?
|
Pneumonia | 2 | 2023 | 2140 | 0.770 |
Why?
|
Licensure, Medical | 1 | 2021 | 71 | 0.740 |
Why?
|
Financing, Government | 1 | 2024 | 472 | 0.730 |
Why?
|
Pharmacy Service, Hospital | 1 | 2022 | 134 | 0.730 |
Why?
|
Drug Substitution | 1 | 2022 | 290 | 0.650 |
Why?
|
Insulin | 3 | 2023 | 6602 | 0.640 |
Why?
|
Cost Savings | 2 | 2021 | 913 | 0.600 |
Why?
|
Biological Products | 2 | 2024 | 912 | 0.590 |
Why?
|
Research Subjects | 1 | 2019 | 249 | 0.570 |
Why?
|
Anti-Asthmatic Agents | 1 | 2022 | 573 | 0.570 |
Why?
|
Medicare | 7 | 2024 | 6770 | 0.560 |
Why?
|
Patient Selection | 3 | 2019 | 4244 | 0.530 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2024 | 12143 | 0.510 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 928 | 0.490 |
Why?
|
Disclosure | 1 | 2021 | 748 | 0.480 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1862 | 0.480 |
Why?
|
Vaccines | 1 | 2023 | 837 | 0.480 |
Why?
|
Educational Measurement | 1 | 2021 | 1254 | 0.470 |
Why?
|
Stroke | 4 | 2017 | 9756 | 0.470 |
Why?
|
Illusions | 1 | 2014 | 61 | 0.460 |
Why?
|
Patient Care Planning | 1 | 2019 | 908 | 0.450 |
Why?
|
Drug Combinations | 3 | 2024 | 2048 | 0.430 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 10203 | 0.430 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13637 | 0.420 |
Why?
|
Lithium Compounds | 1 | 2014 | 223 | 0.420 |
Why?
|
Disease-Free Survival | 1 | 2023 | 6814 | 0.420 |
Why?
|
Physician's Role | 1 | 2019 | 916 | 0.410 |
Why?
|
Humans | 61 | 2024 | 761423 | 0.410 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 8000 | 0.400 |
Why?
|
Drug Labeling | 2 | 2024 | 248 | 0.390 |
Why?
|
Androstadienes | 2 | 2024 | 348 | 0.390 |
Why?
|
Hallucinations | 1 | 2014 | 366 | 0.390 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1640 | 0.390 |
Why?
|
Feedback | 1 | 2015 | 791 | 0.370 |
Why?
|
Antimanic Agents | 1 | 2014 | 520 | 0.360 |
Why?
|
Ependymoma | 1 | 2013 | 320 | 0.350 |
Why?
|
Medical Records | 1 | 2015 | 1407 | 0.330 |
Why?
|
Health Expenditures | 4 | 2023 | 2366 | 0.320 |
Why?
|
Insurance, Pharmaceutical Services | 2 | 2022 | 348 | 0.310 |
Why?
|
Commerce | 2 | 2023 | 606 | 0.300 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2019 | 1461 | 0.300 |
Why?
|
Emergency Medical Services | 1 | 2019 | 1923 | 0.290 |
Why?
|
Spinal Neoplasms | 1 | 2013 | 716 | 0.280 |
Why?
|
Faculty, Medical | 1 | 2015 | 1202 | 0.270 |
Why?
|
Clinical Competence | 1 | 2021 | 4793 | 0.260 |
Why?
|
Research Design | 3 | 2023 | 6178 | 0.240 |
Why?
|
Indomethacin | 1 | 2024 | 326 | 0.230 |
Why?
|
Brain Ischemia | 1 | 2017 | 3049 | 0.230 |
Why?
|
Glycopyrrolate | 1 | 2023 | 32 | 0.220 |
Why?
|
Therapeutic Equivalency | 1 | 2023 | 134 | 0.220 |
Why?
|
Orphan Drug Production | 1 | 2024 | 48 | 0.220 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 153 | 0.210 |
Why?
|
Famotidine | 1 | 2022 | 17 | 0.210 |
Why?
|
Muscarinic Antagonists | 1 | 2023 | 135 | 0.210 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2023 | 111 | 0.210 |
Why?
|
Hospital Charges | 1 | 2024 | 351 | 0.200 |
Why?
|
Medicare Part B | 1 | 2023 | 117 | 0.190 |
Why?
|
Albuterol | 1 | 2022 | 213 | 0.190 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5840 | 0.190 |
Why?
|
Students, Medical | 1 | 2015 | 1930 | 0.190 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2024 | 364 | 0.190 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 49 | 0.190 |
Why?
|
Neoplasms | 3 | 2024 | 22164 | 0.190 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2024 | 793 | 0.180 |
Why?
|
Ethics, Research | 1 | 2022 | 176 | 0.180 |
Why?
|
Immunization Schedule | 1 | 2021 | 227 | 0.180 |
Why?
|
Costs and Cost Analysis | 3 | 2022 | 1668 | 0.180 |
Why?
|
Public Opinion | 1 | 2024 | 484 | 0.170 |
Why?
|
Research Support as Topic | 1 | 2024 | 697 | 0.170 |
Why?
|
Aged | 13 | 2024 | 169235 | 0.170 |
Why?
|
Formularies as Topic | 1 | 2020 | 94 | 0.170 |
Why?
|
Herpes Zoster | 1 | 2021 | 253 | 0.160 |
Why?
|
State Medicine | 1 | 2020 | 216 | 0.160 |
Why?
|
Insurance Benefits | 1 | 2020 | 187 | 0.150 |
Why?
|
Time Factors | 6 | 2023 | 39975 | 0.150 |
Why?
|
Standard of Care | 1 | 2021 | 550 | 0.140 |
Why?
|
Prescriptions | 1 | 2020 | 386 | 0.140 |
Why?
|
Clinical Protocols | 1 | 2023 | 1440 | 0.140 |
Why?
|
Bipolar Disorder | 1 | 2014 | 5091 | 0.140 |
Why?
|
Government Regulation | 1 | 2021 | 524 | 0.130 |
Why?
|
Cohort Studies | 6 | 2024 | 41446 | 0.130 |
Why?
|
Hospital Costs | 1 | 2022 | 948 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 9277 | 0.120 |
Why?
|
Antihypertensive Agents | 1 | 2024 | 2023 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 1 | 2023 | 1876 | 0.120 |
Why?
|
Influenza Vaccines | 1 | 2021 | 767 | 0.110 |
Why?
|
Adult | 8 | 2024 | 221148 | 0.110 |
Why?
|
Basal Ganglia Diseases | 1 | 2014 | 145 | 0.110 |
Why?
|
Canada | 1 | 2019 | 2120 | 0.110 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1580 | 0.110 |
Why?
|
Drug Therapy, Combination | 1 | 2023 | 6309 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1385 | 0.110 |
Why?
|
Perceptual Disorders | 1 | 2014 | 198 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3882 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1896 | 0.090 |
Why?
|
Male | 9 | 2024 | 360736 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2024 | 5492 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2020 | 1669 | 0.090 |
Why?
|
Influenza, Human | 1 | 2021 | 1521 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 26112 | 0.090 |
Why?
|
Public Health | 1 | 2023 | 2666 | 0.090 |
Why?
|
False Negative Reactions | 1 | 1990 | 573 | 0.080 |
Why?
|
Female | 9 | 2024 | 392581 | 0.080 |
Why?
|
Middle Aged | 7 | 2024 | 220826 | 0.080 |
Why?
|
Clinical Clerkship | 1 | 2015 | 564 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2013 | 1784 | 0.080 |
Why?
|
Syndrome | 1 | 2014 | 3268 | 0.070 |
Why?
|
False Positive Reactions | 1 | 1990 | 957 | 0.070 |
Why?
|
Pandemics | 2 | 2023 | 8641 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3249 | 0.070 |
Why?
|
Education, Medical, Undergraduate | 1 | 2015 | 1066 | 0.060 |
Why?
|
Suppositories | 1 | 2024 | 16 | 0.060 |
Why?
|
Primary Health Care | 1 | 2020 | 4686 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20093 | 0.050 |
Why?
|
Omeprazole | 1 | 2022 | 105 | 0.050 |
Why?
|
Child | 2 | 2024 | 80162 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8529 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2024 | 421 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8223 | 0.040 |
Why?
|
France | 1 | 2021 | 498 | 0.040 |
Why?
|
Survival Rate | 1 | 2013 | 12720 | 0.040 |
Why?
|
England | 1 | 2020 | 527 | 0.040 |
Why?
|
Prognosis | 2 | 2024 | 29620 | 0.040 |
Why?
|
Legislation, Drug | 1 | 2021 | 214 | 0.040 |
Why?
|
Deductibles and Coinsurance | 1 | 2021 | 316 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 15498 | 0.040 |
Why?
|
Rare Diseases | 1 | 2024 | 621 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2024 | 80582 | 0.040 |
Why?
|
Hospital Mortality | 2 | 2022 | 5291 | 0.040 |
Why?
|
Young Adult | 1 | 2024 | 59207 | 0.040 |
Why?
|
Proton Pump Inhibitors | 1 | 2022 | 531 | 0.040 |
Why?
|
Research Personnel | 1 | 2022 | 588 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2021 | 741 | 0.030 |
Why?
|
Age Factors | 1 | 2013 | 18400 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1203 | 0.030 |
Why?
|
Adolescent | 1 | 2024 | 88313 | 0.030 |
Why?
|
Mass Screening | 1 | 1990 | 5428 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2273 | 0.030 |
Why?
|
Massachusetts | 1 | 2024 | 8832 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2928 | 0.020 |
Why?
|
Risk Assessment | 2 | 2024 | 23990 | 0.020 |
Why?
|
Models, Statistical | 1 | 2024 | 5077 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2021 | 1940 | 0.020 |
Why?
|
Quality of Life | 1 | 1990 | 13361 | 0.020 |
Why?
|
Critical Care | 1 | 2021 | 2697 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2723 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4650 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2024 | 4811 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10498 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2013 | 64651 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2024 | 15838 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10194 | 0.020 |
Why?
|
Hospitalization | 1 | 2024 | 10718 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7389 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14026 | 0.010 |
Why?
|
Life Style | 1 | 1990 | 3914 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 58956 | 0.010 |
Why?
|